Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | LPAR1 | Q92633 | 8/20 | 0.63 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.63 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LPAR6 | P43657 | 4/20 | 0.50 |
| ▸ | LPAR4 | Q99677 | 4/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18738907 | 0.93 | LPAR1 (0.55) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL11314764 | 0.92 | LPAR1 (0.63) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL10558616 | 0.91 | HTT (0.69) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL12653855 | 0.90 | TSHR (0.60) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL4879843 | 0.90 | LPAR1 (0.68) | HTTLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL4204833 | 0.90 | LPAR1 (0.68) | HTTLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL303128 | 0.90 | LPAR1 (0.68) | HTTLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL8636551 | 0.90 | LPAR1 (0.68) | HTTLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL4294185 | 0.90 | LPAR1 (0.68) | HTTLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL7563995 | 0.90 | LPAR1 (0.68) | HTTLPAR1LPAR3LPAR2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277611-A1 | Cationic cardiolipin analoges and its use thereof | NEOPHARM, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| EP-1558562-A1 | CATIONIC CARDIOLIPIN ANALOGS AND USE THEREOF | Neopharm, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004035523-A1 | CATIONIC CARDIOLIPIN ANALOGS AND USE THEREOF | NEOPHARM, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277611-A1 | Cationic cardiolipin analoges and its use thereof | LCLAT1, CETP, LIPA | HTT 2639/4885MEN1 974/4885THRB 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.